Innovating Works
HORIZON-HLTH-2024-TOOL-11...
HORIZON-HLTH-2024-TOOL-11-02: Bio-printing of living cells for regenerative medicine
ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed towards and contributing to several of the following expected Outcomes:
Sólo fondo perdido 0 €
European
This call is closed This line is already closed so you can't apply. It closed last day 11-04-2024.
An upcoming call for this aid is expected, the exact start date of call is not yet clear.
Hace más de 12 mes(es) del cierre y aún no tenemos información sobre los proyectos financiados, no parece que se vaya a publicar esta información.
Presentation: Consortium Consortium: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Minimum number of participants.
This aid finances Proyectos:

ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed towards and contributing to several of the following expected Outcomes:

Biomedical scientists will access entire bio-printing units for regenerating human tissue.Availability of larger-scale bio-printed tissues for biomedical research purposes to both industry and academia.Healthcare professionals acquire information on the safe and effective use of advanced therapies.Healthcare providers dispose of tools enabling them to treat conditions of unmet medical need.Individual patients will benefit from a personalised approach to their respective medical condition thanks to the bio-printed regenerative medicine solution.
Scope:Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs... see more

ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed towards and contributing to several of the following expected Outcomes:

Biomedical scientists will access entire bio-printing units for regenerating human tissue.Availability of larger-scale bio-printed tissues for biomedical research purposes to both industry and academia.Healthcare professionals acquire information on the safe and effective use of advanced therapies.Healthcare providers dispose of tools enabling them to treat conditions of unmet medical need.Individual patients will benefit from a personalised approach to their respective medical condition thanks to the bio-printed regenerative medicine solution.
Scope:Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function". 3D-printing in general is considered an advanced manufacturing technique and 3D-printing of non-viable biomaterials to serve e.g. as scaffold for cell growth or as structure for medical devices is already broadly used.

However, bio-printing technology involving living cells is still in early stages of development, but has a huge potential for tissue engineering, drug testing and other biomedical applications. Tissue-specific functional 3D bio-printing is a new approach for transplantation applications in regenerative medicine, relying on the fabrication of tissues and organs with respect to the desired shape and function and their delivery and application in vivo. “In-situ bio-printing” known as printing cells and biomaterials directly onto or in a patient, or 4D bio-printing, which introduces a “time” variable that allows 3D printed materials to change shape or function when external stimulus is applied, are recent developments facing multiple additional challenges.

Despite some success of 3D bio-printing with thin tissue, thick tissue and complex organs remain a bottleneck because it is difficult to sufficiently mimic their metabolic needs, and the scientific knowledge about their intimate architecture and interplay with other tissues are not sufficiently elucidated. Next to these limitations are a lack of standardised manufacturing protocols and standardised bio-ink formulations with tuneable properties, unstable cellular behaviour, material biocompatibility and printability, etc. Taken together, 3D bio-printing is confronted with several challenges that currently hamper its large-scale deployment.

To overcome these challenges, researchers should work in multidisciplinary teams with engineers, biomedical scientists, cell biologists and medical doctors and proposals should address most of the following activities:

Design the best bio-printing strategy for at least one type of tissue thanks to a better understanding of the interconnections of the different cell types inside the chosen tissue or organDevelop or improve existing equipment able to print bio-constructs with higher resolution in a shorter time using various biomaterials and different cell typesCover all steps of the bio-printing suite, including cell collection, cell differentiation and expansion, imaging, modelling, bio-ink formulation, actual bio-printing, nutrient supply, process monitoring and cell-construct delivery at target siteScale-up the chosen bio-printing technology to a GMP-conform manufacturing processCombine different bio-printing technologies in order to obtain fully functional synthetic constructs of complex tissues or organs. Regulatory knowledge of the field is desired and should be documented through contacts with relevant national or international European regulatory authorities.

The chosen medical area (tissue, organ, condition) should be duly justified. Sex differences at the cellular level should be taken into consideration.

Preclinical stage and early clinical development are eligible. The involvement of SMEs is encouraged.

Applicants envisaging to include clinical studies should provide details of their clinical studies in the dedicated annex using the template provided in the submission system. See definition of clinical studies in the introduction to this work programme part.


see less

Temáticas Obligatorias del proyecto: Temática principal:
ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed towards and contributing to several of the following expected Outcomes: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed towards and contributing to several of the following expected Outcomes:
Digital Agenda Regenerative medicine Tissue engineering Health-related biotechnology Personalised treatment Biomedical engineering Regenerative Medicine Tissue Engineering Health-related Biotechnology Personalised Treatment Biomedical Engineering Digital Solutions for Health Regenerative Medicine Research Tissue Engineering Innovations Biotechnological Advancements in Health Personalised Medicine Development Biomedical Engineering Applications Personalised Medicine Biotechnology

Consortium characteristics

Scope European : The aid is European, you can apply to this line any company that is part of the European Community.
Tipo y tamaño de organizaciones: The necessary consortium design for the processing of this aid needs:

characteristics of the Proyecto

Requisitos de diseño: *Presupuesto para cada participante en el proyecto
Requisitos técnicos: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed towards and contributing to several of the following expected Outcomes: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed towards and contributing to several of the following expected Outcomes:
Financial Chapters: The chapters of financing expenses for this line are:
Personnel costs.
Expenses related to personnel working directly on the project are based on actual hours spent, based on company costs, and fixed ratios for certain employees, such as the company's owners.
Subcontracting costs.
Payments to external third parties to perform specific tasks that cannot be performed by the project beneficiaries.
Purchase costs.
They include the acquisition of equipment, amortization, material, licenses or other goods and services necessary for the execution of the project
Other cost categories.
Miscellaneous expenses such as financial costs, audit certificates or participation in events not covered by other categories
Indirect costs.
Overhead costs not directly assignable to the project (such as electricity, rent, or office space), calculated as a fixed 25% of eligible direct costs (excluding subcontracting).
Madurez tecnológica: The processing of this aid requires a minimum technological level in the project of TRL 4:. Los componentes que integran determinado proyecto de innovación han sido identificados y se busca establecer si dichos componentes individuales cuentan con las capacidades para actuar de manera integrada, funcionando conjuntamente en un sistema. + info.
TRL esperado:

Characteristics of financing

Intensidad de la ayuda: Sólo fondo perdido + info
Lost Fund:
For the eligible budget, the intensity of the aid in the form of a lost fund may reach as minimum a 100%.
The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations. The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations.
Guarantees:
does not require guarantees
No existen condiciones financieras para el beneficiario.

Additional information about the call

incentive effect: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
non -competitive competitive Very competitive
We do not know the total budget of the line
Financial Projects In this call.
minimis: Esta línea de financiación NO considera una “ayuda de minimis”. You can consult the regulations here.
Certificado DNSH: Los proyectos presentados a esta línea deben de certificarse para demostrar que no causan perjuicio al medio ambiente. + info

other advantages

SME seal: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
deduction R&D+i:
0% 25% 50% 75% 100%
Ark + info
HORIZON-HLTH-2024-TOOL-11 Bio-printing of living cells for regenerative medicine ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Sin info.
HORIZON-HLTH-2024-TOOL-11-02 Bio-printing of living cells for regenerative medicine
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada does 1 year | next call scheduled for the month of
HORIZON-HLTH-2024-TOOL-05-06-two-stage Innovative non-animal human-based tools and strategies for biomedical research
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada does 1 year | next call scheduled for the month of